Seong-Jin Yu

Dr. Seong-Jin Yu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in GeroScience
Verified
Journal Article
Open access
PDF file
SYSeong-Jin Yu
Seong-Jin Yu
YWYun Wang
Yun Wang
HSHui Shen
Hui Shen
EBEun-Kyung Bae
Eun-Kyung Bae
YLYAZHOU LI
YAZHOU LI
NGNigel H Greig
Nigel H Greig
Epidemiological studies report an elevated risk of Parkinson's disease (PD) in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed dipeptidyl peptidase 4 (DPP-4) inhibitors. With an objective to characterize clinically translatable doses of DPP-4 inhibitors (gliptins) in a well-characterized PD rodent model, sitagliptin, PF-00734,200 or vehicle were orally administered to rats initiated either 7-days before or 7-days after unilateral medial forebrain bundle 6-hydroxydopamine (6-OHDA) lesioning. Measures of dopaminergic cell viability, dopamine content, neuroinflammation and neurogenesis were evaluated thereafter in ipsi- and contralateral brain. Plasma and brain incretin and DPP-4 activity levels were quantified. Furthermore, brain incretin receptor levels were age-dependently evaluated in rodents, in 6-OHDA challenged animals and human subjects with/without PD. Cellular studies evaluated neurotrophic/neuroprotective actions of combined incretin administration. Pre-treatment with oral sitagliptin or PF-00734,200 reduced methamphetamine (meth)-induced rotation post-lesioning and dopaminergic degeneration in lesioned substantia nigra pars compacta (SNc) and striatum. Direct intracerebroventricular gliptin administration lacked neuroprotective actions, indicating that systemic incretin-mediated mechanisms underpin gliptin-induced favorable brain effects. Post-treatment with a threefold higher oral gliptin dose, likewise, mitigated meth-induced rotation, dopaminergic neurodegeneration and neuroinflammation, and augmented neurogenesis. These gliptin-induced actions associated with 70–80% plasma and 20–30% brain DPP-4 inhibition, and elevated plasma and brain incretin levels. Brain incretin receptor protein levels were age-dependently maintained in rodents, preserved in rats challenged with 6-OHDA, and in humans with PD. Combined GLP-1 and GIP receptor activation in neuronal cultures resulted in neurotrophic/neuroprotective actions superior to single agonists alone. In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD.

2 January 2020 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
KWKou-Jen Wu
Kou-Jen Wu
YCYun-Hsiang Chen
Yun-Hsiang Chen
EBEun-Kyung Bae
Eun-Kyung Bae
YSYoungHa Song
YoungHa Song
WMWonKi Min
WonKi Min
SYSeong-Jin Yu
Seong-Jin Yu

Verified
Journal Article
Open access
PDF file
SYSeong-Jin Yu
Seong-Jin Yu
KWKuo-Jen Wu
Kuo-Jen Wu
YWYu-Syuan Wang
Yu-Syuan Wang
JSJen-Shin Song
Jen-Shin Song
CWChien-Huang Wu
Chien-Huang Wu
YWYun Wang
Yun Wang
Intracerebral hemorrhage (ICH) is a major cause of stroke, with high mortality and morbidity. There is no effective pharmacological therapy for ICH. Previous studies have indicated that CXCR4 antagonists reduced microglia activation, attenuated infiltration of T cells, and improved functional recovery in ischemic stroke animals. The interaction of CXCR4 antagonists and ICH has not been characterized. The purpose of this study is to examine the neuroprotective action of a novel CXCR4 antagonist CX807 against ICH. In primary cortical neuronal and BV2 microglia co-culture, CX807 reduced glutamate-mediated neuronal loss and microglia activation. Adult rats were locally administered with collagenase VII to induce ICH. CX807 was given systemically after the ICH. Early post-treatment with CX807 improved locomotor activity in ICH rats. Brain tissues were collected for qRTPCR and histological staining. ICH upregulated the expression of CXCR4, CD8, TNFα, IL6, and TLR4. The immunoreactivity of IBA1 and CD8, as well as TUNEL labeling, were enhanced in the perilesioned area. CX807 significantly mitigated these responses. In conclusion, our data suggest that CX807 is neuroprotective and anti-inflammatory against ICH. CX807 may have clinical implications for the treatment of hemorrhagic stroke.

21 June 2021 in Genes
Verified
Journal Article
Open access
PDF file
YCYun-Hsiang Chen
Yun-Hsiang Chen
KWKuo-Jen Wu
Kuo-Jen Wu
WHWei Hsieh
Wei Hsieh
BHBrandon Keith Harvey
Brandon Keith Harvey
BHBarry Hoffer
Barry Hoffer
SYSeong-Jin Yu
Seong-Jin Yu
Accumulation of α-Synuclein (αSyn) in nigral dopaminergic neurons is commonly seen in patients with Parkinson′s disease (PD). We recently reported that transduction of intracellular single-chain intrabody targeting the 53–87 amino acid residues of human αSyn by recombinant adeno associated viral vector (AAV-NAC32) downregulated αSyn protein in SH-SY5Y cells and rat brain. This study characterizes the behavioral phenotype and dopaminergic protection in animals receiving AAV-NAC32. Our results show that adult DAT-Cre rats selectively overexpress αSyn in nigra dopaminergic neurons after local administration of AAV-DIO-αSyn. These animals develop PD-like phenotype, including bradykinesia and loss of tyrosine hydroxylase (TH) immunoreactivity in substantia nigra pars compacta dorsal tier (SNcd). An injection of AAV-NAC32 to nigra produces a selective antibody against αSyn and normalizes the behavior. AAV-NAC32 significantly increases TH, while reduces αSyn immunoreactivity in SNcd. Altogether, our data suggest that an AAV-mediated gene transfer of NAC32 antibody effectively antagonizes αSyn-mediated dopaminergic degeneration in nigra, which may be a promising therapeutic candidate for synucleinopathy or PD.

1 December 2013 in NeuroToxicology
Verified
Journal Article
Closed access
YHYi He
Yi He
SYSeong-Jin Yu
Seong-Jin Yu
EBEunkyung Bae
Eunkyung Bae
HSHui Shen
Hui Shen
YWYun Wang
Yun Wang

6 November 2014 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
SYSeong-Jin Yu
Seong-Jin Yu
KWKou‐Jen Wu
Kou‐Jen Wu
EBEun K. Bae
Eun K. Bae
MHMan‐Jung Hsu
Man‐Jung Hsu
CRChristopher T. Richie
Christopher T. Richie
YWYun Wang
Yun Wang